中国卫生标准管理
中國衛生標準管理
중국위생표준관리
China Health Standard Management
2015年
26期
77-78
,共2页
益赛普%风湿免疫疾病%临床状况%安全性
益賽普%風濕免疫疾病%臨床狀況%安全性
익새보%풍습면역질병%림상상황%안전성
Etanercept%Rheumatoid immune diseases%Clinical conditions%Security
目的：观察益赛普治疗风湿免疫疾病患者的临床状况和安全性。方法100例风湿免疫疾病患者，分为观察组和对照组各50例。对照组进行常规治疗，观察组在此基础上加上益赛普。结果观察组治疗效果明显提高，药物安全性高，两组对比差异具有统计学意义（P＜0.05）。结论对患有风湿免疫疾病的患者进行益普赛治疗，治疗效果明显提高，可以减少药物产生的毒副作用，安全性高，说明益普赛治疗风湿免疫疾病具有良好效果。
目的：觀察益賽普治療風濕免疫疾病患者的臨床狀況和安全性。方法100例風濕免疫疾病患者，分為觀察組和對照組各50例。對照組進行常規治療，觀察組在此基礎上加上益賽普。結果觀察組治療效果明顯提高，藥物安全性高，兩組對比差異具有統計學意義（P＜0.05）。結論對患有風濕免疫疾病的患者進行益普賽治療，治療效果明顯提高，可以減少藥物產生的毒副作用，安全性高，說明益普賽治療風濕免疫疾病具有良好效果。
목적：관찰익새보치료풍습면역질병환자적림상상황화안전성。방법100례풍습면역질병환자，분위관찰조화대조조각50례。대조조진행상규치료，관찰조재차기출상가상익새보。결과관찰조치료효과명현제고，약물안전성고，량조대비차이구유통계학의의（P＜0.05）。결론대환유풍습면역질병적환자진행익보새치료，치료효과명현제고，가이감소약물산생적독부작용，안전성고，설명익보새치료풍습면역질병구유량호효과。
ObjectiveTo observe the clinical status and safety of etanercept in the treatment of patients with rheumatic diseases.Methods 100 patients with rheumatoid immune disease, divided into observation group and control group 50 cases each. The control group routine treatment, observation group based on the combined with etanercept.Results The treatment effect of observation group was obviously improved, drug safety, compared the two groups statisticaly significant difference (P<0.05).Conclusion For patients with rheumatoid immune diseases at the treatment with etanercept , the treatment effect is improved obviously, and can reduce the side effects of drugs, high safety, explain at treating rheumatoid immune disease has good effect, is worth in clinical promotion and application.
